GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
On Monday, the U.S. Food and Drug Administration (FDA) agreed to review GSK plc’s (NYSE:GSK) application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk.
Benzinga ·